Research graph
References from FGF21 and GDF15 alongside conventional cardiac biomarkers in myocardial dysfunction and cardiovascular risk in type 2 diabetes: A systematic review and meta-analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
Association of biomarkers and risk scores with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus
10.1186/s12933-022-01711-5 · 2022 · External reference
Subclinical left ventricular dysfunction over seven-year follow-up in type 2 diabetes patients without cardiovascular diseases
10.3390/biomedicines12092031 · 2024 · External reference
Assessment of subclinical left ventricle myocardial dysfunction using global myocardial work in type 2 diabetes mellitus patients with preserved left ventricle ejection fraction
10.1186/s13098-021-00781-x · 2022 · External reference
Quantitative analysis of myocardial work by non-invasive left ventricular pressure-strain loop in patients with type 2 diabetes mellitus
10.3389/fcvm.2021.733339 · 2021 · External reference
Left ventricular subclinical myocardial dysfunction in uncomplicated type 2 diabetes mellitus is associated with impaired myocardial perfusion: a contrast-enhanced cardiovascular magnetic resonance study
10.1186/s12933-018-0782-0 · 2018 · External reference
Cardiac magnetic resonance T1 mapping for evaluating myocardial fibrosis in patients with type 2 diabetes mellitus: correlation with left ventricular longitudinal diastolic dysfunction
10.1007/s00330-022-08800-9 · 2022 · External reference
Assessment of left ventricular deformation in patients with type 2 diabetes mellitus by cardiac magnetic resonance tissue tracking
10.1038/s41598-020-69977-x · 2020 · External reference
Diagnostic performance of serum biomarkers fibroblast growth factor 21, galectin-3 and copeptin for heart failure with preserved ejection fraction in a sample of patients with type 2 diabetes mellitus
10.3390/diagnostics11091577 · 2021 · External reference
Predictive value of NT-proBNP, FGF21, galectin-3 and copeptin in advanced heart failure in patients with preserved and mildly reduced ejection fraction and type 2 diabetes mellitus
10.3390/medicina60111841 · 2024 · External reference
Contribution of serum FGF21 level to the identification of left ventricular systolic dysfunction and cardiac death
10.1186/s12933-017-0588-5 · 2017 · External reference
Circulating fibroblast growth factor 21 is associated with diastolic dysfunction in heart failure patients with preserved ejection fraction
10.1038/srep33953 · 2016 · External reference
Serum fibroblast growth factor 21 is predictive of combined cardiovascular morbidity and mortality in patients with type 2 diabetes at a relatively short-term follow-up
10.1016/j.diabres.2013.04.010 · 2013 · External reference
The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate intervention and Event Lowering in Diabetes study
10.1007/s00125-014-3458-7 · 2015 · External reference
Prognostic impact of fibroblast growth factor 21 in patients with heart failure
10.1253/circrep.cr-25-0067 · 2025 · External reference
Role of circulating fibroblast growth factor 21 measurement in primary prevention of coronary heart disease among Chinese patients with type 2 diabetes mellitus
10.1161/jaha.116.005344 · 2017 · External reference
Usefulness of growth differentiation factor-15 levels to predict diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes mellitus
10.1016/j.amjcard.2014.06.020 · 2014 · External reference
Diabetes, GDF-15 and incident heart failure: the atherosclerosis risk in communities study
10.1007/s00125-022-05678-6 · 2022 · External reference
Circulating levels of GDF-15 for predicting cardiovascular and cancer morbidity and mortality in type 2 diabetes: findings from Da Qing IGT and diabetes study
10.1016/j.diabet.2022.101380 · 2022 · External reference
Targeted multiple biomarker approach in predicting cardiovascular events in patients with diabetes
10.1136/heartjnl-2015-308949 · 2016 · External reference
Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach
10.1080/03009734.2019.1696430 · 2020 · External reference
Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes - an observational follow-up study
10.1371/journal.pone.0196634 · 2018 · External reference
Association between circulating GDF-15 and cardio-renal outcomes and effect of canagliflozin: results from the CANVAS trial
10.1161/jaha.121.021661 · 2021 · External reference
Clinical and biomarker predictors of expanded heart failure outcomes in patients with type 2 diabetes mellitus after a recent acute coronary syndrome: insights from the EXAMINE trial
10.1161/jaha.119.012797 · 2020 · External reference
Effects of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and their combination on neurohumoral and mitochondrial activation in patients with diabetes
10.1161/jaha.124.039129 · 2025 · External reference
Global longitudinal strain and plasma biomarkers for prognosis in heart failure complicated by diabetes: a prospective observational study
10.1186/s12872-024-03810-5 · 2024 · External reference
Circulating growth differentiation factor-15 levels are associated with early echocardiographic signs of diastolic function impairment in the STANISLAS cohort: a 20-year follow-up study
10.1002/ejhf.3576 · 2025 · External reference
Unresolved reference
2026 · External reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
2021 · External reference
Meta-analysis of observational studies in epidemiology: a proposal for reporting
10.1001/jama.283.15.2008 · 2000 · External reference
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
10.7326/0003-4819-155-8-201110180-00009 · 2011 · External reference
Assessing bias in studies of prognostic factors
10.7326/0003-4819-158-4-201302190-00009 · 2013 · External reference
Meta-analysis in clinical trials
10.1016/0197-2456(86)90046-2 · 1986 · External reference
A basic introduction to fixed-effect and random-effects models for meta-analysis
10.1002/jrsm.12 · 2010 · External reference
Unresolved reference
External reference
Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews
10.1016/j.jclinepi.2005.02.022 · 2005 · External reference
Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): explanation, elaboration, and checklist
2020 · External reference
Measuring inconsistency in meta-analyses
10.1136/bmj.327.7414.557 · 2003 · External reference
Bias in meta-analysis detected by a simple, graphical test
10.1136/bmj.315.7109.629 · 1997 · External reference
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials
10.1136/bmj.d4002 · 2011 · External reference
A nonparametric trim and fill method of accounting for publication bias in meta-analysis
2000 · External reference
